Dr. Andrea Small-Howard

Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current roles as the Chief Science Officer and member of the Board of Directors at both GB Sciences, Inc. (OTCQB:GBLX) and their newly-formed, Canadian subsidiary, GBS Global Biopharma, Inc. (Ottawa, Canada).

Dr. Small-Howard brings to GBS her passion for advancing clinical research on medicinal applications of cannabinoid compounds, pre-clinical experience in conducting cannabinoid research, a track record of successes in the management of biopharmaceutical companies, and a strategic vision for creating a novel drug discovery engine and biopharmaceutical drug development program for disease-specific, cannabis-based therapeutics.

Dr. Andrea Small-Howard, Chief Science Officer and Director, GB Sciences, Inc. (OTCQB: GBLX) and Chief Science Officer and Director of GBS Global Biopharma, Inc. (Ottawa, Canada)

Dr. Small-Howard has more than 20 years’ experience studying cannabinoids and the endocannabinoid system, immunology and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing and quality control divisions in both US and global divisions. She took the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (“US FDA”) and numerous international regulatory agencies; and she has assisted multiple state jurisdictions in developing medical cannabis regulations.
Dr. Small-Howard received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All-University Merit Fellow) in biological sciences from USC. As a post-doctoral fellow, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published peer-reviewed papers on the subject. Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As VP of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic product development and regulatory oversight across multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements. For a four-year term, she served on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.